comparemela.com
Home
Live Updates
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML : comparemela.com
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track...
Related Keywords
Spain ,
Alexandra Weingarten ,
Troy Wilson ,
Nasdaq ,
Kura Oncology Inc ,
Drug Administration ,
Globenewswire Inc ,
Linkedin ,
Exchange Commission ,
Corporate Communications ,
Breakthrough Therapy Designation ,
Chief Executive Officer ,
Orphan Drug Designation ,
Vice President ,
Investor Relations ,
Breakthrough Therapy ,
Markets ,
comparemela.com © 2020. All Rights Reserved.